Aptus Capital Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.5M Sell
75,380
-4,402
-6% -$616K 0.08% 199
2025
Q4
$9.79M Buy
79,782
+2,702
+4% +$328K 0.07% 214
2025
Q3
$8.56M Buy
77,080
+54,526
+242% +$6.2M 0.06% 233
2025
Q2
$2.5M Buy
22,554
+3,879
+21% +$413K 0.02% 386
2025
Q1
$2.09M Buy
18,675
+374
+2% +$38.6K 0.02% 387
2024
Q4
$1.69M Buy
18,301
+10,038
+121% +$904K 0.02% 424
2024
Q3
$693K Buy
8,263
+309
+4% +$23.6K 0.01% 477
2024
Q2
$546K Sell
7,954
-807
-9% -$53.9K 0.01% 490
2024
Q1
$642K Sell
8,761
-52,321
-86% -$4.02M 0.01% 460
2023
Q4
$4.95M Sell
61,082
-80
-0.1% -$6.22K 0.14% 134
2023
Q3
$4.58M Sell
61,162
-2,224
-4% -$171K 0.12% 140
2023
Q2
$4.89M Buy
63,386
+59,286
+1,446% +$4.73M 0.12% 145
2023
Q1
$340K Sell
4,100
-530
-11% -$43.9K 0.01% 372
2022
Q4
$397K Buy
4,630
+191
+4% +$15.1K 0.01% 372
2022
Q3
$274K Buy
+4,439
New +$280K 0.01% 397
2022
Q2
Sell
-2,869
Closed -$171K 690
2022
Q1
$171K Buy
+2,869
New +$183K ﹤0.01% 435
2020
Q3
Sell
-2,687
Closed -$206K 483
2020
Q2
$206K Sell
2,687
-1,088
-29% -$83.4K 0.01% 259
2020
Q1
$282K Sell
3,775
-2,980
-44% -$206K 0.02% 233
2019
Q4
$438K Sell
6,755
-23,445
-78% -$1.53M 0.03% 280
2019
Q3
$1.91M Sell
30,200
-4,531
-13% -$296K 0.11% 130
2019
Q2
$2.35M Buy
34,731
+3,179
+10% +$209K 0.33% 48
2019
Q1
$2.05M Buy
31,552
+9,614
+44% +$639K 0.35% 56
2018
Q4
$1.37M Buy
+21,938
New +$1.53M 0.36% 50

Other funds holding GILD

Aptus Capital Advisors's GILD Position: Q1 2026 in Review

Aptus Capital Advisors reduced its Gilead Sciences (GILD) stake by 5.5% in Q1 2026, selling an estimated $616K and leaving 75,380 shares worth $10.5M. The position accounts for 0.08% of the portfolio, ranked #199.

Aptus Capital Advisors first reported a position in GILD in Q4 2018 and has held it in 23 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Aptus Capital Advisors held 75,380 shares of Gilead Sciences worth $10.5M as of Q1 2026.
  • Aptus Capital Advisors sold 4,402 Gilead Sciences shares in Q1 2026, an estimated $616K.
  • Gilead Sciences made up 0.08% of Aptus Capital Advisors's portfolio in Q1 2026, its #199 holding.
  • Aptus Capital Advisors first reported a position in Gilead Sciences in Q4 2018 and has held it in 23 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.